A. Zyryanov

Safety and ef fi cacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as fi rst-line therapy in patients with advanced non-small-cell lung cancer

M. Gore, V. Matveev, J. Bellmunt, 2013 .

A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN.

M. Gore, B. Melichar, V. Matveev, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

BEVLiN: Prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-α2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC).

M. Gore, B. Melichar, V. Matveev, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors.

G. Manikhas, A. Komissarov, O. Kiselev, 2017, Oncotarget.

Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors

G. Manikhas, A. Komissarov, O. Kiselev, 2017, Oncotarget.